Role of PCIF1-mediated 5′-cap N6-methyladeonsine mRNA methylation in colorectal cancer and anti-PD-1 immunotherapy

ABSTRACT: Adenosine N6-methylation (m6A) and N6,2′-O-dimethylation (m6Am) are regulatory modifications of eukaryotic mRNAs. m6Am formation is catalysed by the methyl transferase phosphorylated CTD-interacting factor 1 (PCIF1); however, the pathophysiological functions of this RNA modification and PCIF1 in cancers are unclear. Here, we show that PCIF1 expression is upregulated in colorectal cancer (CRC) and negatively correlates with patient survival. CRISPR/Cas9-mediated depletion of PCIF1 in human CRC cells leads to loss of cell migration, invasion, and colony formation in vitro and loss of tumor growth in athymic mice. Pcif1 knockout in murine CRC cells inhibits tumor growth in immunocompetent mice and enhances the effects of anti-PD-1 antibody treatment by decreasing intra-tumoral TGF-β levels, a

SUBMITTER: Dr. Lingling Wang 

PROVIDER: S-SCDT-10_15252-EMBJ_2022111673 | biostudies-other |

REPOSITORIES: biostudies-other